@article{WinterKunzeVeitetal.2023,
  author    = {Jochen Winter and Rudolf Kunze and Nadine Veit and Stefan Kuerpig and Michael Meisenheimer and Dominik Kraus and Alexander Glassmann and Rainer Probstmeier},
  title     = {Targeting of Glucose Transport and the NAD Pathway in Neuroendocrine Tumor (NET) Cells Reveals New Treatment Options},
  series   = {Cancers},
  volume    = {15},
  number    = {5},
  publisher = {MDPI},
  address   = {Basel},
  issn      = {2072-6694},
  doi       = {10.3390/cancers15051415},
  url       = {https://nbn-resolving.org/urn:nbn:de:hbz:1044-opus-66405},
  year      = {2023},
  abstract  = {Background: the potency of drugs that interfere with glucose metabolism, i.e., glucose transporters (GLUT) and nicotinamide phosphoribosyltransferase (NAMPT) was analyzed in neuroendocrine tumor (NET, BON-1, and QPG-1 cells) and small cell lung cancer (SCLC, GLC-2, and GLC-36 cells) tumor cell lines. (2) Methods: the proliferation and survival rate of tumor cells was significantly affected by the GLUT-inhibitors fasentin and WZB1127, as well as by the NAMPT inhibitors GMX1778 and STF-31. (3) Results: none of the NET cell lines that were treated with NAMPT inhibitors could be rescued with nicotinic acid (usage of the Preiss–Handler salvage pathway), although NAPRT expression could be detected in two NET cell lines. We finally analyzed the specificity of GMX1778 and STF-31 in NET cells in glucose uptake experiments. As previously shown for STF-31 in a panel NET-excluding tumor cell lines, both drugs specifically inhibited glucose uptake at higher (50 μM), but not at lower (5 μM) concentrations. (4) Conclusions: our data suggest that GLUT and especially NAMPT inhibitors are potential candidates for the treatment of NET tumors.},
  language  = {en}
}